Company intelligence / Profile preview
Suzhou Huyun New Drug Research and Development
Suzhou, Jiangsu Province, Chinaadisinsight.springer.com ↗
- Ownership
- Private
- Development stage
- Phase 3
01
Overview
The company has a drug called Borneol (SPT-07A) in Phase III clinical trials for stroke. The most recent development was in January 2022 when Phase III clinical trials were initiated in China for stroke treatment in adults and elderly patients.
- Therapeutic areas
- Neurology
- Modalities
- Small moleculesTraditional Chinese medicine
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Suzhou Huyun New Drug Research and Development.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Suzhou Huyun New Drug Research and Development.